Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients

This study tests whether diacerein (brand name Artrodar), an anti-inflammatory medication, can slow the structural deterioration of knee cartilage in people with knee osteoarthritis by measuring total cartilage volume on MRI scans over 2 years. Osteoarthritis is the most common form of joint disease and currently lacks effective disease-modifying treatments. Adults aged 40 to 65 with a diagnosis of primary knee osteoarthritis of moderate severity (Kellgren-Lawrence grade II or III), a BMI of 30 or below, and adequate knee pain on walking may be eligible, while those with inflammatory joint diseases, recent joint injections, severe gastrointestinal disorders, or kidney or liver impairment are excluded. Participation involves taking one capsule daily (then two daily after a month) over 2 years, with MRI scans and regular clinical assessments to track cartilage changes and symptoms. This summary was generated with AI assistance to help patients understand the study in plain language.